Fifth Third Bancorp Raises Position in Charles River Laboratories International, Inc. $CRL

Fifth Third Bancorp boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 51.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,733 shares of the medical research company’s stock after buying an additional 6,002 shares during the quarter. Fifth Third Bancorp’s holdings in Charles River Laboratories International were worth $3,059,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CRL. Invesco Ltd. raised its stake in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA bought a new position in Charles River Laboratories International during the 4th quarter valued at about $176,478,000. Victory Capital Management Inc. raised its position in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares during the period. Ameriprise Financial Inc. raised its position in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares during the period. Finally, Norges Bank bought a new stake in Charles River Laboratories International in the fourth quarter worth about $96,765,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.0%

CRL opened at $219.91 on Tuesday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock’s fifty day moving average is $193.76 and its two-hundred day moving average is $186.77. The company has a market capitalization of $10.59 billion, a P/E ratio of -58.49, a PEG ratio of 2.50 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $237.86.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Insider Activity

In related news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research analyst reports. Evercore reissued an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Finally, Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $220.75.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.